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Over 3 million people died of AIDS 
last year and about 5 million others 
became infected with HIV, bringing 
the total number of people living with 
the infection to nearly 40 million. The 
continuing rise in the number of new 
cases makes it a priority to investigate all 
possible measures that might reduce the 
risk of infection, particularly—but by no 
means only—in Africa, which has 10% of 
the world’s population but two-thirds of 
the world’s people with HIV. 
In many African tribal groups, men are 
circumcised, usually in late childhood 
or as teenagers, and this is an important 
part of their cultural identity. In other 
African ethnic groups, men are not 
circumcised. From observational 
studies dating back to the 1980s, it has 
become clear that HIV infection rates 
are greater in those groups where men 
were not circumcised. It has, however, 
remained a matter of speculation as to 
whether it is circumcision itself or some 
other difference in behavior that has a 
protective effect. What has been needed 
to settle this question is a randomized 
controlled trial (RCT) of the use of 
circumcision as a preventive intervention.
Auvert et al. have completed the ﬁ  rst 
such trial in the Orange Farm area, a 
semiurban region close to Johannesburg, 
South Africa. They offered young, 
heterosexual uncircumcised men the 
chance to have the operation, explaining 
that half of those who came forward 
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Mitochondrial DNA (mtDNA) has been intensively studied over 
the past two decades, and point mutations, more commonly 
known as deletions, of this DNA are known to be involved in 
several syndromes. Unlike nuclear DNA, with 46 chromosomes, 
half from each parent, mtDNA is just one piece of genome of 
which there are many copies, but all copies come only from the 
mother. Mitochondrial disease syndromes, such as MELAS, have 
a range of different clinical manifestations depending on how 
many copies of the abnormal mtDNA are present in affected 
cells. 
There are several international resources of mtDNA sequences. 
From these sequences, it has been possible to show that different 
population groups have different patterns of substitutions in the 
mtDNA—so-called haplogroups; this information has been used, 
for example, in the investigation of the origin and migration 
patterns of human populations, and some investigators have 
even suggested that it could be used to trace back to earliest 
human history the founding mothers of humanity. 
More recently, however, attention has turned to the question 
of whether mtDNA is involved in tumor formation. However, 
deciding whether mutations are harmful or innocuous has 
been difﬁ  cult. One concern is that isolation of mtDNA from any 
tissue is not simple, and may be particularly difﬁ  cult from tumor 
samples, which are often contaminated with exogenous DNA. 
In a hard-hitting paper, Antonio Salas and colleagues cast 
more doubt over a causal role for mtDNA alterations in tumors; 
they have now reassessed many of the studies that have 
examined the role of mtDNA in tumorigenesis, and concluded 
that much of the data are at best questionable. The group used 
a phylogenetic approach to analyze the reported work, which 
compared the sequences under consideration with the current 
database of complete sequences of mtDNA. The authors believe 
that such an approach is essential to look at the overall picture 
of the mtDNA rather than assessing each substitution in the 
mtDNA independently.
Salas and colleagues conclude that more than 80% of 
published mtDNA sequencing studies contain obvious errors, 
and that many of the published results that implicate mutations 
in tumorigenesis are in fact part of normal population variability, 
and their presence must be due to contamination of the tumor 
sample. Salas does not hold back in his criticisms. He states that 
the result of such sequencing “disasters” is that ﬂ  awed results 
are not ﬁ  ltered out from the clinical literature, which makes the 
task of interpreting the role of mtDNA in the tumor process very 
difﬁ  cult. 
The researchers draw analogies to the time when ancient DNA 
sequencing was beginning, and many contaminated samples 
were ampliﬁ  ed and claimed to yield prehistoric DNA. They urge 
clinical geneticists to use checks similar to those proposed to 
assess authenticity for ancient DNA studies: special care should 
be taken in sequencing and documentation, raw sequence data 
should be made fully accessible to referees and readers, and 
the complete record of data from the population genetics ﬁ  eld 
should be used to put the results in context.
The group’s ﬁ  ndings will undoubtedly cause much debate in 
this research community. With their conclusion that “there is no 
precedent that we know of in the genetics literature for such a 
high number of ﬂ  awed papers (most of them published in high-
rank journals), which affect a whole subﬁ  eld of clinical research,” 
they urge reconsidering the role of mtDNA in tumorigenesis.
Salas A, Yao YG, Macaulay V, Vega A, Carracedo Á, et al. (2005) A 
critical reassessment of the role of mitochondria in tumorigenesis. 
DOI: 10.1371/journal.pmed.0020296
Casting Doubt on the Role of Mitochondria in Tumorigenesis
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would be circumcised straightaway and 
the others (the control group) 21 months 
later. Some 3,000 men joined the study. 
It was planned that all the men would 
visit the research clinic four times during 
this 21-month period, and that they 
would be tested for HIV each time. They 
were instructed not to have sex for six 
weeks after the operation, and asked 
at each clinic visit to provide detailed 
information about their sexual activity. 
However, after 17 months, the number of 
new infections in the control group (49) 
was so much greater than the number 
in the treatment group (20) that it was 
considered unethical to continue the 
study, which was thus terminated early. 
Since infections were 60% lower in the 
treatment group, we now have strong 
evidence favoring the use of circumcision 
as part of prevention efforts. 
Preliminary results from the Orange 
Farm study were presented in July 
at the 3rd International AIDS Society 
Conference in Rio de Janeiro, where 
there was considerable interest in the 
ﬁ  ndings, although some cautionary notes 
were also sounded. Some observers 
have expressed concerns that the 
researchers did not tell participants of 
their HIV status, although they gave 
them every encouragement to attend a 
counseling and testing clinic in order to 
ﬁ  nd this out. These and other issues are 
discussed in our accompanying Editorial 
(DOI: 10.1371/journal.pmed.0020293) 
and in two Perspectives, one by Peter 
Cleaton-Jones (DOI: 10.1371/journal.
pmed.0020287), chair of the ethics 
committee that approved the study, 
and the second by Nandi Siegfried (DOI: 
10.1371/journal.pmed.0020393), lead 
author of a Cochrane systematic review 
of male circumcision for prevention of 
heterosexual acquisition of HIV in men.
The authors have called for the 
promotion of male circumcision as part of 
AIDS prevention efforts in Orange Farm 
and in other parts of Africa. However, 
others will take a more cautious view, 
believing that the positive results of this 
one study must be conﬁ  rmed by further 
studies. Such trials are currently under 
way in Kenya and Uganda. We must also 
remember that adult circumcision carries 
risks, especially if performed by medical 
personnel or traditional healers without 
proper training. A further concern is that 
circumcised men, considering themselves 
to be “protected,” might be more likely 
to engage in unsafe sex. Research is 
also needed to ﬁ  nd out whether male 
circumcision has a preventive effect 
only on female-to-male transmission, 
or whether it may also reduce male-to-
female transmission or male-to-male 
transmission. In addition, it will be 
important to determine the mechanism 
by which circumcision exerts its apparent 
protective effect. 
Many questions do therefore remain, 
but in the words of one of the study’s 
peer reviewers, this ﬁ  rst RCT may come to 
be regarded as “a landmark paper” in HIV 
prevention.
Auvert B, Taljaard D, Lagarde E, Sobngwi-
Tambekou J, Sitta R, et al. (2005) 
Randomized, controlled intervention trial 
of male circumcision for reduction of HIV 
infection risk: The ANRS 1265 trial. DOI: 
10.1371/journal.pmed.0020298
Imagine the eye is like a camera. The shutter, like the iris of 
the eye, opens and closes to let in the right amount of light. 
The lens helps focus light on the ﬁ  lm. And the ﬁ  lm is like the 
retina. Regardless of the quality of the camera, if the ﬁ  lm is 
faulty, the developed pictures may be distorted or blurred. In 
this way, untreatable degenerative diseases of the retina, which 
affect millions of people worldwide, lead to varying degrees 
of irreversible blindness. These degenerative eye disorders 
include retinitis pigmentosa, which affects 1.5 million people, 
and age-related macular degeneration, which is a leading 
cause of blindness in North America. The list of inherited retinal 
dystrophies (degenerations) is long and includes Best disease, 
choroideremia, cone–rod dystrophy, congenital stationary night 
blindness, and Leber congenital amaurosis (LCA).
LCA is a collection of diseases all characterized by severe loss 
of vision at birth from retinal dysfunction. It is a leading cause 
of congenital blindness. Currently, there is no treatment for LCA; 
however, it is known that LCA can be caused by mutations in the 
gene encoding RPE65, a key protein involved in the production 
and recycling of the chromophore 11-cis-retinal (11-cis-RAL)
in the eye. 11-cis-RAL is an integral part of rhodopsin and cone 
visual pigments, pigments essential for our vision. About 15% 
of patients with LCA have mutations in RPE65. Humans with 
this form of LCA and Rpe65-deﬁ  cient mice models both have 
severely impaired rod and cone function. 
Armed with this knowledge, scientists are honing in on various 
therapeutic strategies for genetic eye diseases. These strategies 
include somatic gene therapy, infusion of protective proteins, and 
embryonic cell transplantation. The hope is that such interventions 
will converge and lead to treatments that slow down or prevent 
the blindness characteristic of many degenerative eye diseases.
There have been several attempts to restore vision in patients 
with LCA using interventions such as calcium channel blockers 
and intraocular injection of neurotrophic factors. In most cases, 
the effects of these treatments lasted less than a month; hence, 
repeated administrations were required. Another approach is to 
bypass the biochemical block in mice without functional Rpe65 
using synthetic cis-retinoids administered orally; such treatments 
have induced dramatic improvement in photoreceptor physiology.
Tackling Inherited Blindness 
DOI: 10.1371/journal.pmed.0020402
DOI: 10.1371/journal.pmed.0020402.g001
Pharmacological and rAAV Gene Therapy Rescue of the Retinoid 
Cycle
November 2005  |  Volume 2  |  Issue 11  |  e391  |  e402PLoS Medicine  |  www.plosmedicine.org 1052
Many adults living in malaria-endemic areas have acquired 
clinical immunity against the disease: even though they are 
constantly reinfected and frequently carry parasites, they are 
able to control the level of parasitemia and don’t develop 
clinical symptoms. The passive transfer of serum IgG from such 
individuals can confer a similar level of protection to individuals 
without acquired immunity. Searching for the targets of those 
protective antibodies, Pierre Druilhe and colleagues had 
previously identiﬁ  ed Plasmodium falciparum merozoite surface 
protein 3 (MSP3). 
Subsequent work from Druilhe’s group and others provided 
additional support that MSP3 might be a good candidate for 
a malaria vaccine: (1) naturally occurring or artificially raised 
antibodies against MSP3 can, in collaboration with monocytes, 
inhibit parasite growth in vitro, (2) an MSP3-based vaccine 
can confer immunity in primates (and protection correlates 
with anti-MSP3 antibody titers), and (3) anti-MSP3 antibody 
transfer can protect a malaria-susceptible humanized mouse 
model. 
Druilhe and colleagues have now completed the ﬁ  rst human 
trial of an MSP3-based vaccine. Some 30 healthy volunteers 
received three subcutaneous injections, each over several 
months of different doses of MSP3 peptide together with either 
aluminum hydroxide or Montanide ISA720. (Some 36 individuals 
were originally enrolled, but ﬁ  ve of the recipients of MSP3 plus 
Montanide developed local erythema after the second injection 
and, per protocol speciﬁ  cations, received no third injection, and 
a sixth dropped out during the follow-up.) Details of the trial and 
the safety outcome will be published elsewhere (Infect Immun 
73. DOI: 10.1128/IAI.73.12 ). 
Both vaccine formulations induced cellular and humoral 
immune responses in the majority of the volunteers, even at the 
lowest peptide doses. Speciﬁ  c T-cell responses were seen in 29 
of 30 participants, vaccine-speciﬁ  c antibodies developed in 23 
of 30, and 18 of 30 reacted with the parasite native protein. Like 
those of the naturally immune individuals from endemic areas, 
the vaccine-induced antibodies were primarily of the IgG1 and 
IgG3 subclasses. Antibodies elicited by MSP3 plus alum were 
generally of higher afﬁ  nity (compared with the Montanide 
formulation), and similar to those from individuals with acquired 
immunity. Some of the MSP3 plus alum responses lasted for up 
to 12 months. 
To test for functional immunity, Druilhe and colleagues 
showed that serum antibodies from those volunteers who had 
MSP3-speciﬁ  c antibodies were able to inhibit parasite growth in 
collaboration with monocytes. They also tested the antibody in 
vivo in a humanized mouse model and found that they enabled 
parasite clearance from the blood. 
“A particular strength of the MSP3 trial is that functional 
assays were utilized to assess the quality of the antibody 
response produced,” say Brendan Crabb and James Beeson in 
an accompanying Perspective. However, they also point out 
that important questions remain, some of which will only be 
answered in efﬁ  cacy-based trials. Encouraged by the results 
of the initial trial, Druilhe and colleagues have started a phase 
II efﬁ  cacy ﬁ  eld trial of MSP3 plus alum in malaria-exposed 
individuals. The results are eagerly awaited. 
Druilhe P, Spertini F, Soesoe D, Corradin G, Mejia P, et al. (2005) 
A malaria vaccine that elicits in humans antibodies able to kill 
Plasmodium falciparum. DOI: 10.1371/journal.pmed.0020344
Malaria Vaccine Yields Parasite-Killing Antibodies in Human Volunteers
DOI: 10.1371/journal.pmed.0020408
Also, somatic gene therapy has been very successful in 
many animal models of retinal degeneration. In this issue of 
PLoS Medicine, Krzysztof Palczewski and colleagues attempted 
to combine two approaches to restore visual function with 
intraocular gene therapy and oral pharmacologic treatment with 
novel retinoid compounds in lecithin retinol acyl transferase 
(LRAT)–deﬁ  cient mice. LRAT is a key enzyme involved in storage 
of vitamin A in the form of retinyl esters in structures known as 
retinosomes. In mice without LRAT, no 11-cis-RAL chromophore 
is produced, and visual function is severely impaired. Lrat
mutations have been detected in a subset of patients with LCA.
The team found that gene therapy using intraocular injection 
of recombinant adeno-associated virus carrying the Lrat gene 
successfully restored electroretinographic and pupillary light 
responses in Lrat−/− mice. Production of 11-cis-RAL was also 
restored. Pharmacological intervention with orally administered 
pro-drugs 9-cis-retinyl acetate and 9-cis-retinyl succinate also 
caused long-lasting restoration of retinal function in Lrat-
deﬁ  cient mice. Combining interventions produced markedly 
increased levels of visual pigment, and 1,000-fold improvements 
in pupillary light response and electroretinogram sensitivity. 
Direct comparison of each treatment was difﬁ  cult, but both 
therapies provide efﬁ  cient recovery of higher order visual 
responses. One advantage of oral retinoid treatment was its 
ease of administration compared with the subretinal injections 
required for viral vectors. Another factor was that the orally 
administered compounds were not stored in the liver for long, 
and were quickly oxidized and secreted. Pharmacological 
treatment could also be given multiple times; several low-dose 
treatments show cumulative effects. The main disadvantage of 
oral treatment was the potential for long-term systemic toxicity 
compared with vector targeting of LRAT to the RPE, which needs 
to be examined in future studies.
Interestingly, the researchers observed that chromophore 
supplementation and somatic gene therapy were optimally 
effective in combination, particularly when chromophore 
supplementation was continued at low doses for longer periods 
of time. The authors suggest that the combined approach might 
be more suitable for treating a wider age range of patients. 
Although much more preclinical testing is required, it is likely 
that pharmacologic and somatic gene therapeutic approaches 
could be used together if such testing proves safe and successful 
in human trials. The authors speculate that treatment of patients 
with oral retinoids could begin in infancy to avoid amblyopia 
while also avoiding the difﬁ  culties associated with surgery in 
very young patients. For older patients, a long-lasting drug-free 
treatment might be achieved by surgical introduction of viral 
vectors.
Batten ML, Imanishi Y, Tu DC, Doan T, Zhu L, et al (2005) 
Pharmacological and rAAV gene therapy rescue of visual functions in 
a blind mouse model of Leber congenital amaurosis. DOI: 10.1371/
journal.pmed.0020333
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Tyrosine kinases of the epidermal 
growth factor receptor (EGFR) family are 
frequently mutated in human cancers. 
Mutations in the tyrosine kinase domain 
of EGFR (encoded by exons 18–24) have 
mostly been found in lung cancers. Some, 
but not all, lung cancers carrying such 
mutations are responsive to treatment 
with small-molecule EGFR inhibitors, 
including the two FDA-approved drugs 
erlotinib and geﬁ  tinib. 
Matthew Meyerson and colleagues 
undertook a systematic study of the 
different classes of EGFR mutations found 
in lung cancers in order to understand 
their roles in tumorigenesis on one hand, 
and their relation to drug sensitivity 
on the other. They introduced different 
altered EGFR versions into ﬁ  broblast 
and lung epithelial cells, and found that 
all of the mutant proteins transformed 
both cell types in an EGF-independent 
manner. Transformation was associated 
with constitutive kinase activity and with 
the activation of known downstream 
signaling pathways. 
While the various mutant receptors 
had similar transforming capabilities, 
cells expressing them differed in 
their response to EGFR inhibitors. 
Transformation of cells expressing 
mutations in exons 18, 19, and 21 was 
inhibited by 100 nM erlotinib or geﬁ  tinib, 
whereas no signiﬁ  cant inhibitory effect 
on cells expressing an exon 20 insertion 
mutation was seen even at much higher 
concentrations of either drug. This result 
is consistent with the lack of clinical 
responses to erlotinib or geﬁ  tinib in 
three lung cancer patients with exon 
20 mutations. In contrast, when the 
researchers tested another experimental 
EGFR inhibitor called CL-387,785, they 
found cells expressing the exon 20 
insertion mutation to be sensitive, 
consistent with previous studies that had 
found similar patterns with other EGFR 
exon 20 mutations. 
These results highlight the problems 
and the possibilities of individualized 
cancer therapy. One drug is unlikely to 
ﬁ  t all tumors, not even all tumors with 
mutations in a speciﬁ  c oncogene. On the 
other hand, having a collection of drugs 
against a particular target increases 
chances that one of them will prove 
effective, and that alternatives exist when 
tumors develop resistance. Developing 
such a collection and selecting the 
right drug for the right patient is a 
challenge not only scientiﬁ  cally but also 
economically. 
Greulich H, Chen TH, Feng W, Jänne 
PA, Alvarez JV, et al. (2005) Oncogenic 
transformation by inhibitor-sensitive and 
-resistant EGFR mutants. DOI: 10.1371/
journal.pmed.0020313
EGFR Mutations and Lung Cancer
DOI: 10.1371/journal.pmed.0020374 
DOI: 10.1371/journal.pmed.0020374.g001
Morphology of ﬁ  broblasts expressing 
mutant EGFR
Measles is still a leading cause of death among young children, 
despite the availability of an effective vaccine for the past 40 
years. Although it is rare in many developed countries, it remains 
a common illness in many developing countries, and more 
than half a million people, mostly children, died from measles 
in 2003. There is a global effort to reduce measles mortality, 
which aims to achieve routine vaccination coverage of at least 
90% of people. In countries with high vaccination coverage, the 
epidemic pattern has changed from a roughly biennial cycle 
to an irregular sequence of outbreaks—mainly from imported 
cases and people refusing vaccination.
A proper understanding of the size and timing of these 
outbreaks is crucial for monitoring a vaccination program 
and assessing the risk of future measles outbreaks. Previous 
studies have shown that the size of an outbreak depends on 
the fraction of susceptible individuals in a population but also 
on chance events in the transmission process. These previous 
studies presupposed the existence of a critical threshold 
level for the fraction of susceptible individuals, below which 
introduction of infection will lead to only minor outbreaks. 
The probability that the outbreak will be major increases 
with the fraction of susceptible individuals in excess of the 
threshold.
In a PLoS Medicine paper, Jacco Wallinga and colleagues stress 
the need for direct observations that show the relationship 
between fraction of susceptible individuals and infection attack 
rate during irregular measles outbreaks in highly vaccinated 
populations. Such observations could shed light on how health 
authorities should interpret infection attack rates and assess the 
risk of future measles outbreaks, they say.
To overcome this lack of information, the team investigated 
measles outbreaks over 28 years in a Dutch population. They 
estimated the fraction of susceptible individuals and infection 
attack rates for each epidemic year during the study period. 
The average vaccine coverage during this period was 93%, 
and there was no sustained measles transmission. Several 
Modeling Measles Epidemics
DOI: 10.1371/journal.pmed.0020384
DOI: 10.1371/journal.pmed.0020384.g001
Relation between fraction of susceptible individuals and attack rate
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measles outbreaks occurred in communities with low vaccine 
coverage, but these ended without intervention. The team 
found a clear threshold value for the fraction of susceptible 
individuals below which only minor outbreaks occurred, 
and above which both minor and major outbreaks occurred. 
They suggest that a precise quantitative relationship exists 
between the fraction of susceptible individuals in excess 
of this threshold and the infection attack rate during major 
outbreaks: one additional unvaccinated person is associated 
with more than one—almost two—infected persons in 
subsequent major outbreaks.
These findings update previous thinking on measles 
vaccination strategies. Previous approaches relied on a 
statistical description of outbreak sizes based on the theory 
of solid herd immunity in a homogeneous population. 
However, the authors’ observations are suggestive of 
occasional, localized lapses in herd immunity, which would 
allow for major outbreaks within communities with low 
vaccine coverage. The authors suggest that major outbreaks 
can be averted only if additional vaccination programs, 
first tested in mathematical models, target communities at 
risk, or if measles cases are prevented from entering those 
communities.
The authors warn that great care should be taken in 
interpreting a time series of measles case notiﬁ  cations without 
a corresponding time series of the fraction of susceptible 
individuals. A few measles cases over several years might not 
necessarily signal that solid herd immunity has been achieved. 
It might in fact indicate an increasing risk of a future major 
measles outbreak. Therefore, these ﬁ  ndings could also be 
used to improve the design of disease-surveillance systems by 
including monitoring of the changes in fraction of susceptible 
individuals through time. And whenever the transmission chain 
is interrupted, the estimated change in fraction of susceptible 
individuals could be used to assess the risk of future major 
measles outbreaks.
Wallinga J, Heijne JCM, Kretzschmar M (2005) A measles epidemic 
threshold in a highly vaccinated population. DOI: 10.1371/journal.
pmed.0020316
There are 123 million women around 
the world, mostly in developing countries, 
who are not using contraception in spite 
of having expressed a desire to space or 
limit the numbers of their births. About 
38% of all pregnancies worldwide every 
year are unintended, and around six out 
of ten such unplanned pregnancies result 
in an abortion. By helping women to 
exercise their reproductive rights, family 
planning programs can improve the 
social and economic circumstances of 
women and their families.
Often contraception is available 
only in family planning clinics and 
hospitals, where it is given by trained 
providers; however, worldwide supplies 
of contraceptives are available from 
diverse places. Studies have suggested 
that conventional family planning clinics 
might discourage some groups, such as 
younger people, from using their facilities, 
an observation backed by ﬁ  ndings that 
report high awareness of contraception 
in some communities but low usage. 
But other barriers to contraceptive use 
include cultural issues, religion, cost, 
husband/partner’s refusal, availability, 
accessibility, and fear of side effects.
In PLoS Medicine, Boniface A. Oye-
Adeniran and colleagues say that a better 
understanding of families’ preferences 
for certain distribution centers would 
enable providers to deliver better service. 
And getting contraceptives, especially 
condoms, closer to people in acceptable, 
culturally sensitive, and friendly 
environments could not be more urgent 
than now, with the need to contain the 
HIV/AIDS pandemic.
The team did a community-based 
study to examine the sources of 
contraceptives for users in Nigeria to 
identify whether there was a preference 
for some distribution centers. Of the 
2001 respondents aged 15–49 years, 
1,647 (82.3%) were sexually active, 
out of which only 244 (14.8%) were 
using contraception at the time of the 
study. The team found some striking 
trends. Most respondents got their 
contraceptives from chemist/patent 
medicine shops (19.7%), whereas only 
0.8% went to family planning clinics. 
Married respondents preferred hospitals, 
health centers, and clinics—perhaps 
indicating their need for long-term 
contraception, that is, intrauterine 
devices and injectables. However, young 
unmarried respondents, who preferred 
condoms and pills, went to pharmacies 
and over-the-counter services.
The small number of respondents 
who got their contraceptives from 
family planning clinics was worrying, 
but showed a similar trend to Ghana, 
where there was also a shift from public 
to private sources. One factor for this 
development might be general staff 
attitude in clinics, said the authors, and 
the lack of youth-friendly services.
There were religious differences in 
usage: Catholics and Muslims preferred to 
use chemists/patent medicine shops for 
contraceptives rather than hospitals and 
clinics, which may have had something 
to do with their religions’ disapproval 
of contraceptive use. The age of the 
respondent was also very important in 
how individuals obtained contraceptives. 
Most adolescents preferred chemist/
patent medicine shops, but at 25 years 
of age and older, more people went 
to general or private hospitals. This 
behavior perhaps reﬂ  ected a cultural 
disapproval of sex when unmarried, the 
group to which most of these young 
persons belong. The authors noted that 
the most popular contraceptives for 
younger age groups (condoms and pills) 
were also available over the counter. 
The observations in this age group are 
particularly relevant, said the authors, 
since 15–24 year olds have the greatest 
incidence of unwanted pregnancy and 
unsafe abortion.
Altogether, the study highlighted the 
inadequate information and counseling 
on the various types of contraceptive 
methods in Nigeria. The authors suggest 
that when planning contraceptive 
services, planners must take into account 
the sources of contraception identiﬁ  ed 
here, and work on improving culturally 
relevant delivery methods, such as youth-
friendly clinics.
Oye-Adeniran A, Adewole IF, Umoh AV, 
Oladokun A, Gbadegesin A, et al. (2005) 
Sources of contraceptive commodity for 
users in Nigeria. DOI: 10.1371/journal.
pmed.0020306
Where Do People Get Their Information and Contraceptives From?
DOI: 10.1371/journal.pmed.0020382
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The resurgence of malaria remains a major global concern. 
Artemisinin-based drugs are increasingly seen as one of the 
best hopes for, at last, making progress in the battle against 
malaria. Trials of artemisinin-based combination therapy 
(ACT) in control programs in Southeast Asia have been very 
encouraging. However, we need to know whether similar levels 
of effectiveness are achievable in Africa, where the majority of 
the world’s cases of malaria are found.
One part of Africa that has seen increases both in the number 
of malaria cases and in drug resistance is South Africa’s KwaZulu–
Natal province. The rise in malaria in this area has been dramatic, 
with a 15–fold increase in cases taking place during the 1990s. 
Control efforts during this period involved mosquito control with 
pyrethroid insecticides (which had replaced DDT) and sulfadoxine-
pyrimethamine (SP) as a ﬁ  rst-line treatment. (SP was introduced in 
1988 in response to high levels of chloroquine resistance.) 
In the year 2000, new measures were put in place to address 
KwaZulu–Natal’s malaria crisis. The key elements of this new 
strategy were the introduction of an ACT drug, artemether-
lumefantrine (AL), and an intensiﬁ  cation of mosquito control 
efforts. While pyrethroids were retained for indoor residual 
spraying of western-style structures, DDT was also reintroduced 
for spraying traditional homesteads. Karen Barnes and colleagues 
now present the ﬁ  rst comprehensive description and evaluation 
of the program.
The researchers reviewed four years of malaria morbidity and 
mortality data at four representative health-care facilities within 
KwaZulu–Natal’s malaria-endemic area. They found that, in the 
year following improved vector control and implementation of 
AL treatment, malaria-related admissions and deaths declined 
by 89%, and outpatient visits decreased by 85%. By 2003, 
malaria-related outpatient cases and admissions had fallen by 
99%, and malaria-related deaths had decreased by 97%. There 
was a marked and sustained decline in malaria throughout 
the province. AL cured 99% of those study patients who were 
followed up for 42 days. Consistent with the ﬁ  ndings of focus 
group discussions, a household survey found that self-reported 
adherence to the six-dose AL regimen was 96%. Two surveys 
in subsets of patients receiving AL revealed no serious adverse 
events resulting from the treatment.
These are impressive results, but they are not solely due to 
the introduction of ACT. As the authors say, “the ready access to 
treatment in a relatively well-developed rural primary health-
care infrastructure, coupled with an effective vector control 
programme [are] important factors for deriving the greatest 
beneﬁ  t from ACT implementation. Equally important are the 
strong community perceptions that malaria diagnosis and 
treatment should be sought urgently at public health-care 
facilities and treatment then completed.” 
In an accompanying Perspective (DOI: 10.1371/journal.
pmed.0020368), Patrick Duffy and Theonest Mutabingwa highlight 
lessons learned from the “notable success” in KwaZulu–Natal “amid 
the dire statistics showing a deadly resurgence of malaria.” They 
also discuss how economic and noneconomic conditions in other 
parts of sub-Saharan Africa differ from KwaZulu–Natal in ways that 
are likely to affect the inﬂ  uence of ACT. 
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Artemisinin is extracted from Artemisia annua, the annual 
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